Recent 8-K filings for KEQU
Highest-materiality recent filing
Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line
- Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.
- PNC financing includes $20M revolver and $15M term loan maturing Nov 2029; seller notes mature in 3 years.
-
Kewaunee Scientific Q3 sales +3.3% to $69.4M; diluted EPS $0.23 vs $0.45; backlog down 17% YoY
Sales $69.4M (+3.3% YoY); pre-tax earnings $1.6M (+25.8%).
-
Kewaunee Scientific Q2 FY2026: sales +46.8% to $70.1M, diluted EPS $0.82 vs $1.01
Sales up 46.8% to $70.1M; net earnings $2.45M (-18.7%); diluted EPS $0.82 (vs $1.01).
-
Kewaunee repays $23M seller notes early with new $10M term loan and revolver draw
Entered First Amendment with PNC Bank for additional $10M term loan and revolver access to fund repayment.
-
Kewaunee Scientific Q1 sales up 47%; EPS $1.04; backlog $205M; expects FY EBITDA increase
Sales $71.1M (+46.9% YoY); diluted EPS $1.04 vs $0.74; net earnings $3.09M.
-
Kewaunee Scientific Q4 sales up 36% to $77.1M; EPS $1.63, backlog $214.6M
Q4 sales $77.1M, +36% YoY; pre-tax earnings $7.1M vs $1.3M prior year quarter (which included non-recurring pension charge).
-
Kewaunee Q3 revenue +44% to $67.2M; adj. diluted EPS $1.09 vs $0.85
GAAP diluted EPS $0.45 vs $0.85; net earnings $1.4M vs $2.5M; includes $2.5M Nu Aire acquisition & integration costs.
-
Kewaunee closes Nu Aire acquisition for $55M; audited Nu Aire FY24 net income $5.44M
Kewaunee acquired Nu Aire for $55M on Nov 1, 2024, using $35M bank financing and $23M seller notes at 8%.
-
Net sales $47.8M (down 5.3% YoY); domestic sales up 6.5%, international down 30.1% due to India construction delays.
-
Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line
Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.
-
Kewaunee Q4 sales up 5%, adjusted EPS $1.55 vs $0.34; backlog rises to $155.6M
Q4 sales $56.7M (+5% YoY); GAAP net earnings $11.0M (diluted EPS $3.71) include two non-recurring items.
-
Kewaunee Q3 FY2024 EPS $0.85 vs $0.25 YoY; net income triples despite 23% sales drop
Sales $46.8M, down 23% YoY from $60.8M; net income $2.5M vs $0.7M.
-
Kewaunee Scientific swings to Q2 profit of $2.7M; EPS $0.93 vs -$0.09
Sales $50.4M, down 7.6% YoY; net earnings $2.7M vs loss of $243K.
-
Kewaunee Scientific Q1 net earnings $2.47M vs loss of $0.75M YoY; EPS $0.86 vs ($0.27)
Net earnings of $2.47M ($0.86 diluted EPS) vs net loss of $0.75M ($0.27 loss) in prior Q1.
-
Kewaunee Scientific posts Q4 profit of $0.34/share; FY revenue up 30% to $219.5M
Q4 net earnings $1,005,000 ($0.34 diluted EPS) vs net loss of $362,000 ($0.13 loss) in prior year.
-
Kewaunee Q3 net income $723K ($0.25 EPS) vs loss; sales up 49.7%
Net earnings $723K ($0.25 diluted EPS) vs net loss $1,319K (-$0.47); sales $60.8M, +49.7% YoY.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.45 · Most common event earnings